↓ Skip to main content

Cochrane Database of Systematic Reviews

Tocilizumab for rheumatoid arthritis

Overview of attention for article published in Cochrane database of systematic reviews, July 2010
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (64th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 X user
wikipedia
3 Wikipedia pages

Citations

dimensions_citation
62 Dimensions

Readers on

mendeley
207 Mendeley
connotea
1 Connotea
Title
Tocilizumab for rheumatoid arthritis
Published in
Cochrane database of systematic reviews, July 2010
DOI 10.1002/14651858.cd008331.pub2
Pubmed ID
Authors

Jasvinder A Singh, Saba Beg, Maria Angeles Lopez‐Olivo

Abstract

Tocilizumab, a new biologic that inhibits interleukin-6, is approved for treatment of rheumatoid arthritis (RA) in Europe, Japan and the US. To assess the efficacy and safety of tocilizumab in patients with RA using the data from published randomized or quasi-randomized controlled trials (RCTs). We performed a search of the following databases: the Cochrane Central Register of Controlled Trials (CENTRAL) up to issue 3, 2009; OVID MEDLINE(1966 to 1 October 2009); CINAHL(1982 to 2009); EMBASE (1980 to week 39, 2009); Science Citation Index (Web of Science) (1945 to 2009) and Current Controlled Trials. Tocilizumab alone or in combination with disease-modifying anti-rheumatic drugs (DMARDs) or biologics compared to placebo or other DMARDs or biologics. Two review authors independently extracted all data including major (ACR50, adverse events, serious adverse events, withdrawals, specific adverse events) and secondary outcomes. We calculated the risk ratio for dichotomous outcomes and mean difference for continuous outcomes. Eight RCTs were included in this systematic review with 3334 participants; 2233 treated with tocilizumab and 1101 controls. Of the 2233, 1561 were treated with tocilizumab 8 mg/kg every four weeks, which is the approved dose. In patients taking concomitant methotrexate, compared to placebo, tocilizumab-treated patients were four times more likely to achieve ACR50 (absolute %, 38.8% versus 9.6%), 11 times more likely to achieve Disease Activity Score (DAS) remission (absolute %, 30.5% versus 2.7%), 1.8 times more likely to achieve clinically meaningful decrease in Health Assessment Questionnaire (HAQ/mHAQ) scores (absolute %, 60.5% versus 34%), 1.2 times more likely to have any adverse event (absolute %, 74% versus 65%) and 0.6 times less likely to withdraw from therapy for any reason (absolute %, 8.1% versus 14.9%). With the limitation that none of the studies were powered for safety as primary outcome, there were no statistically significant differences in serious adverse effects, or withdrawals due to adverse events. A significant increase in total, HDL and LDL cholesterol and triglyceride level was seen in the tocilizumab treated patients. Tocilizumab is beneficial in decreasing RA disease activity and improving function. Tocilizumab treatment was associated with significant increase in cholesterol levels and in total adverse events. Larger safety studies are needed to address these safety concerns.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 207 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Germany 2 <1%
Australia 1 <1%
Brazil 1 <1%
Singapore 1 <1%
Sri Lanka 1 <1%
Belgium 1 <1%
Unknown 200 97%

Demographic breakdown

Readers by professional status Count As %
Student > Master 35 17%
Researcher 23 11%
Student > Ph. D. Student 22 11%
Student > Bachelor 22 11%
Other 14 7%
Other 39 19%
Unknown 52 25%
Readers by discipline Count As %
Medicine and Dentistry 84 41%
Nursing and Health Professions 15 7%
Agricultural and Biological Sciences 8 4%
Psychology 7 3%
Biochemistry, Genetics and Molecular Biology 6 3%
Other 25 12%
Unknown 62 30%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 June 2023.
All research outputs
#7,993,771
of 25,457,297 outputs
Outputs from Cochrane database of systematic reviews
#8,729
of 11,499 outputs
Outputs of similar age
#36,208
of 104,870 outputs
Outputs of similar age from Cochrane database of systematic reviews
#42
of 70 outputs
Altmetric has tracked 25,457,297 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 11,499 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 40.0. This one is in the 22nd percentile – i.e., 22% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 104,870 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.
We're also able to compare this research output to 70 others from the same source and published within six weeks on either side of this one. This one is in the 34th percentile – i.e., 34% of its contemporaries scored the same or lower than it.